Revance therapeutics inc. news: berger montague investigates securities fraud allegations against revance therapeutics inc. (rvnc); lead plaintiff deadline is february 8, 2022

Philadelphia, pennsylvania--(newsfile corp. - january 15, 2022) - berger montague is investigating securities fraud allegations on behalf of investors who purchased the securities of revance therapeutics inc. ("revance" or the "company") (nasdaq: rvnc) between november 25, 2019 through october 11, 2021 (the "class period"). if you purchased revance securities during the class period, would like to discuss berger montague's investigation, or have questions concerning your rights or interests, please contact attorneys andrew abramowitz at aabramowitz@bm.net...
RVNC Ratings Summary
RVNC Quant Ranking